1. Market Research

Expanded Access Programs: Opportunities and Challenges for Pharma

  • April 2015
  • Firstword Pharma
Report ID: 3090957

Summary

Table of Contents




Expanded access programmes make available investigational drugs to chronically sick or dying patients who have no other licenced product or clinical trial alternative. Driven by clinicians and patients, this highly-emotive area has both benefits and risks for pharma. What are the advantages? Where are the dangers? Does pharma have a moral imperative to engage?


Expanded Access Programs: Opportunities and Challenges for Pharma is a detailed report for industry management who must assess, approve or manage expanded access requests and programmes. Enriched with case studies, the report reveals the “real-world” experience and opinions of 17 senior industry, regulatory and stakeholder experts in the US and Europe and presents critical insights on the current operating environment for expanded access programmes.








Key Benefits

Understand clinician and patient drivers for expanded access
Formulate strategies to respond to requests that meet the needs of the wide variety of stakeholders involved
Understand the complex and varying regulatory requirements in leading markets
Balance the risks and “real-world” research benefits of engaging in expanded access programmes
Assess whether running your own expanded access programmes or engaging a service company is the route to go
Review the therapeutic areas currently attracting interest for expanded access programmes
Be aware of the PR benefits and dangers of engaging in expanded access programmes
Understand how “Right to Try” and CURE legislation may impact this area in the US



Answers to Critical Questions

Expanded Access: how best to manage clinician/patient requests?
Regulation of expanded access programmes varies widely in the US and EU – what are the essentials you need to know?
Companies are often expected to foot the bill for expanded access programmes – so what are the research and communication upsides that would support your participation?
What role can service companies play in smoothing access and management between pharma and clinicians/patients?
Avoiding unintentional consequences: how could expanded access impact the main drive to get the compound to market for all patients?
Media can be valuable partners in getting awareness of expanded access programme availability, but can also backfire if things don’t go to plan. How can you manage communications and avoid falling into a PR black hole?


Top Takeaways

Understand the factors that drive patients and clinicians to submit requests for early access to investigational drugs
Be aware of the positive – if complicated - regulatory environment in the US and EU governing early access programmes

Examine the financial implications: you may get paid, but more often you’ll be footing the bill
Learn from “real world” experience on how industry is engaging with expanded access programmes and meeting the challenges they present
Identify the key benefits that accrue in terms of early exposure of your investigational drug in a real world setting
Appreciate how an early access programme can help support and speed your product application, and also how they can slow progress to regulatory approval.


Expert Contributors


Pharma and biotech experts

CEO and Founder, radiopharmaceutical company
Chief Commercial Officer, global biopharmaceutical
Senior Director of Global Pricing and Reimbursement, global biopharmaceutical
CEO, biotechnology company
A representative from a leading biotech company
A representative from a top 15 pharma company
CEO, pharma company
COO, biopharmaceutical company
Senior medical director, pharma company

Service provider experts

Head of Project Management, Global Access Programmes
Senior Vice President, Global Access Programmes
Head, US programme operations
Director, commercial development
Marketing Director
Senior Project Director

Patient advocacy groups

President and co-founder, Marti Nelson Cancer Foundation
President and founder, Melanoma International Foundation

Regulatory authorities

Spokesperson, UK's Medicines and Healthcare Products Regulatory Agency




About FirstWord

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence.



FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.

Learn more at www.firstwordgroup.com.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Ahmad helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.